{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:41:56Z","timestamp":1787312516835,"version":"build-2736575974"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Epidemiological evidence supports a role for statins in improving survival in advanced prostate cancer, particularly among men receiving androgen-ablative therapies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To study the association between statin use and survival among men with prostate cancer receiving androgen deprivation therapy (ADT) or androgen receptor axis\u2013targeted therapies (ARATs).<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n This systemic review and meta-analysis used sources from MEDLINE, EMBASE, Epub Ahead of Print, Cochrane Clinical Trials, Cochrane Systematic Reviews, and Web of Science from inception to September 6, 2022.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Observational studies reporting associations of concurrent statin use and survival outcomes (in hazard ratios [HRs]).<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Two authors independently abstracted all data. Summary estimates pooled multivariable HRs with 95% CIs using the generic inverse variance method with random-effects modeling. A priori specified subgroup and sensitivity analyses were undertaken, and heterogeneity, study quality, and publication bias were evaluated. Confidence in the evidence was assessed using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Overall mortality and prostate cancer\u2013specific mortality (PCSM).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Twenty-five cohorts of 119\u202f878 men (65\u202f488 statin users [55%]) with more than 74\u202f416 deaths were included. Concurrent statin use was associated with a 27% reduction in the risk of overall mortality (HR, 0.73 [95% CI, 0.66-0.82];\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200983%) and a 35% reduction in the risk of PCSM (HR, 0.65 [95% CI, 0.58-0.73];\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200974%), with substantial heterogeneity in both estimates. Subgroup analyses identified a PCSM advantage associated with statins for men receiving ARATs compared with ADT alone (HR, 0.40 [95% CI, 0.30-0.55] vs 0.68 [95% CI, 0.60-0.76];\n P<\/jats:italic>\n = .002 for difference). Confidence in the evidence was rated low for both outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this meta-analysis show that concurrent statin use was associated with reduced overall mortality and PCSM among men receiving androgen-ablative therapies for advanced prostate cancer. These findings are limited by the observational nature of the data and residual unexplained interstudy heterogeneity. Randomized clinical trials are warranted to validate these results.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.42676","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T11:32:44Z","timestamp":1669807964000},"page":"e2242676","source":"Crossref","is-referenced-by-count":25,"title":["Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Viranda H.","family":"Jayalath","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Clark","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Research Institute, Toronto, Ontario, Canada"},{"name":"Division of Surgical Oncology-Urology, Princess Margaret Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lajkosz","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouhi","family":"Fazelzad","sequence":"additional","affiliation":[{"name":"Library Services, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Surgical Oncology-Urology, Princess Margaret Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Klotz","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Surgical Oncology-Urology, Princess Margaret Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"issue":"2","key":"zoi221202r1","first-page":"17","article-title":"Canadian Urological Association\u2013Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.","volume":"14","author":"So","year":"2020","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"zoi221202r3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.eururo.2014.09.022","article-title":"Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model.","volume":"68","author":"Gravis","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"zoi221202r4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrurol.2016.199","article-title":"The current evidence on statin use and prostate cancer prevention: are we there yet?","volume":"14","author":"Alfaqih","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"1","key":"zoi221202r5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030062","article-title":"Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.","volume":"7","author":"Mostaghel","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"zoi221202r6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2015.0829","article-title":"Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer.","volume":"1","author":"Harshman","year":"2015","journal-title":"JAMA Oncol"},{"issue":"13","key":"zoi221202r7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/pros.v77.13","article-title":"The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.","volume":"77","author":"Harshman","year":"2017","journal-title":"Prostate"},{"key":"zoi221202r8","doi-asserted-by":"publisher","first-page":"29106","DOI":"10.1038\/srep29106","article-title":"The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis.","volume":"6","author":"Tan","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"zoi221202r9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/jcpt.v45.3","article-title":"The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone\/enzalutamide: a systematic review and meta-analysis.","volume":"45","author":"Yang","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"7650","key":"zoi221202r13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"zoi221202r14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamaoncol.2017.2752","article-title":"Examining bias in studies of statin treatment and survival in patients with cancer.","volume":"4","author":"Emilsson","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi221202r15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.urolonc.2018.11.017","article-title":"The impact of statins in combination with androgen deprivation therapy in patients with advanced prostate cancer: a large observational study.","volume":"37","author":"Anderson-Carter","year":"2019","journal-title":"Urol Oncol"},{"issue":"9","key":"zoi221202r16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161959","article-title":"Influence of statins on survival outcome in patients with metastatic castration resistant prostate cancer treated with abiraterone acetate.","volume":"11","author":"Boegemann","year":"2016","journal-title":"PLoS One"},{"key":"zoi221202r17","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(14)60956-8","article-title":"972 Effects of prior use of statins in a phase 3 study of intermittent versus continuous combined androgen deprivation.","volume":"13","author":"Calais Da Silva","year":"2014","journal-title":"Eur Urol Suppl"},{"issue":"6","key":"zoi221202r18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.euf.2017.03.015","article-title":"Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate.","volume":"4","author":"Di Lorenzo","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"28","key":"zoi221202r19","doi-asserted-by":"publisher","first-page":"19861","DOI":"10.18632\/oncotarget.v9i28","article-title":"Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.","volume":"9","author":"Gordon","year":"2018","journal-title":"Oncotarget"},{"key":"zoi221202r20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e16045","article-title":"Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).","volume":"32","author":"Hamilton","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi221202r21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2020.12.031","article-title":"The association between statin use and outcomes in patients initiating androgen deprivation therapy.","volume":"79","author":"Hamilton","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"zoi221202r22","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.1016\/j.ijrobp.2019.06.1908","article-title":"Influence of statins on survival outcome in patients with metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors.","volume":"105","author":"Henriquez Lopez","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"zoi221202r23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/pros.v79.6","article-title":"Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.","volume":"79","author":"Joentausta","year":"2019","journal-title":"Prostate"},{"issue":"9","key":"zoi221202r24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4111\/kju.2015.56.9.630","article-title":"Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.","volume":"56","author":"Jung","year":"2015","journal-title":"Korean J Urol"},{"key":"zoi221202r25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.2020.38.6_suppl.205","article-title":"Androgen deprivation therapy and statin therapy in prostate cancer patients.","volume":"38","author":"Lai","year":"2020","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi221202r26","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2016.71.8981","article-title":"Postdiagnosis statin use and mortality in Danish patients with prostate cancer.","volume":"35","author":"Larsen","year":"2017","journal-title":"J Clin Oncol"},{"key":"zoi221202r27","doi-asserted-by":"publisher","first-page":"viii279","DOI":"10.1093\/annonc\/mdy284.018","article-title":"Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial.","volume":"29","author":"Lorente","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"zoi221202r28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/21681805.2017.1362032","article-title":"Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.","volume":"51","author":"Mikkelsen","year":"2017","journal-title":"Scand J Urol"},{"issue":"1-2","key":"zoi221202r29","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.5489\/cuaj.267","article-title":"Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.","volume":"7","author":"Niraula","year":"2013","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"zoi221202r30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41391-021-00351-2","article-title":"Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users: a population-based cohort study.","volume":"24","author":"Peltomaa","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"zoi221202r31","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1158\/1538-7445.AM2019-4468","article-title":"Abstract 4468: role of statins and PSA nadir after androgen-deprivation therapy in overall survival of patients with metastatic prostate cancer.","volume":"79","author":"Siddiqui","year":"2019","journal-title":"Cancer Res"},{"issue":"7","key":"zoi221202r32","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/cam4.v9.7","article-title":"Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer.","volume":"9","author":"Tan","year":"2020","journal-title":"Cancer Med"},{"key":"zoi221202r33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2018.11.032","article-title":"Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy.","volume":"112","author":"Wu","year":"2019","journal-title":"Eur J Cancer"},{"issue":"22","key":"zoi221202r34","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1158\/1078-0432.CCR-20-1967","article-title":"Statins as anticancer agents in the era of precision medicine.","volume":"26","author":"Longo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"zoi221202r35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046691","article-title":"Statin use and risk of prostate cancer: a meta-analysis of observational studies.","volume":"7","author":"Bansal","year":"2012","journal-title":"PLoS One"},{"key":"zoi221202r36","doi-asserted-by":"publisher","first-page":"24521","DOI":"10.1038\/srep24521","article-title":"LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies.","volume":"6","author":"Tan","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"zoi221202r37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41391-018-0053-x","article-title":"Statin use and time to progression in men on active surveillance for prostate cancer.","volume":"21","author":"Jayalath","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"zoi221202r38","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/annonc\/mdt077","article-title":"Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis.","volume":"24","author":"Park","year":"2013","journal-title":"Ann Oncol"},{"issue":"2-3","key":"zoi221202r39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.euf.2016.05.004","article-title":"Statin use and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.","volume":"3","author":"Murtola","year":"2017","journal-title":"Eur Urol Focus"},{"issue":"6","key":"zoi221202r40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2018.06.037","article-title":"Atorvastatin versus placebo for prostate cancer before radical prostatectomy\u2014a randomized, double-blind, placebo-controlled clinical trial.","volume":"74","author":"Murtola","year":"2018","journal-title":"Eur Urol"},{"issue":"39","key":"zoi221202r41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001644","article-title":"Statin use reduces prostate cancer all-cause mortality: a nationwide population-based cohort study.","volume":"94","author":"Sun","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"zoi221202r42","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"zoi221202r43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41391-018-0045-x","article-title":"Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.","volume":"21","author":"Allott","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"zoi221202r44","first-page":"57","article-title":"Practical guide to the use of abiraterone in castration resistant prostate cancer.","volume":"21","author":"Mostaghel","year":"2014","journal-title":"Can J Urol"},{"issue":"16","key":"zoi221202r45","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-16-2245","article-title":"Association of tissue abiraterone levels and SLCO genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer.","volume":"23","author":"Mostaghel","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi221202r46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer.","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"zoi221202r47","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/djn362","article-title":"The influence of statin medications on prostate-specific antigen levels.","volume":"100","author":"Hamilton","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"zoi221202r48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.5489\/cuaj.7975","article-title":"The effect of lowering cholesterol through diet on serum prostate-specific antigen levels: a secondary analysis of clinical trials.","volume":"16","author":"Jayalath","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"zoi221202r49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/21681805.2018.1492967","article-title":"Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy.","volume":"52","author":"Rantaniemi","year":"2018","journal-title":"Scand J Urol"},{"issue":"12","key":"zoi221202r50","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.3390\/cancers14122920","article-title":"Inverse association between statin use and cancer mortality relates to cholesterol level.","volume":"14","author":"Peltomaa","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"zoi221202r52","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(20)30424-1","article-title":"Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy.","volume":"21","author":"Tran","year":"2020","journal-title":"Lancet Oncol"},{"key":"zoi221202r10","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2020","edition":"2nd ed"},{"key":"zoi221202r2","unstructured":"American Urological Association. Advanced prostate cancer: AUA\/ASTRO\/SUO guideline (2020). Updated March 1, 2021. Accessed April 14, 2022. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/advanced-prostate-cancer"},{"key":"zoi221202r11","unstructured":"University of Toronto. Activities exempt from human ethics review. 2019. Accessed April 14, 2022. https:\/\/research.utoronto.ca\/ethics-human-research\/activities-exempt-human-ethics-review"},{"key":"zoi221202r12","unstructured":"Wells? G, Shea B, O\u2019Connell D, . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021. Accessed April 14, 2022. https:\/\/www.ohri.ca\/\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"zoi221202r51","unstructured":"Sch\u00fcnemann H, Brozek J, Guyatt G, Oxman A, eds. GRADE handbook. Updated October 2013. Accessed April 14, 2022. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.su8je886t55g"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2799080\/jayalath_2022_oi_221202_1669128876.33803.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T11:32:54Z","timestamp":1669807974000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799080"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.42676","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}